view iqvia report strong result ahead forecast
consensu core segment continu perform well adjust
impact account chang guidanc reflect solid
expect
result iqvia report result includ revenu ebitda
ep beat revenu outperform forecast street
strength commerci solut solut integr
engag servic slightli trail forecast revenu beat
stronger expect ebitda margin led signific adjust
ebitda beat vs forecast line
item led slightli smaller ep beat vs forecast
street
posit trend iqvia issu guidanc reflect prior
account standard new standard
compar guidanc use prior standard revenu guidanc
bracket street forecast ebitda ep guidanc
ahead street reflect new standard revenu guidanc
 adjust ebitda ep
 guidanc support solid book
report billion gross award ltm
contract book-to-bil metric continu improv book
next-gen capabl alreadi reach billion
adjust estim adjust estim reflect
strength commerci solut busi book
segment account standard lower tax rate
revis revenu estim midpoint guidanc
revis ep estim upper half guidanc
reflect margin expans share repurchas
maintain outperform maintain outperform rate share
increas price target reflect multipl appli
ep estim multipl increas reflect
stronger expect ep growth
valu usd unless otherwis note
price prior trade day market close estimate unless otherwis note
quintilesim creat octob merger
quintil im health busi oper
three segment research develop commerci
solut integr engag servic compani
provid outsourc real-world evid solut
biopharmaceut compani also provid solut
connect healthcar technology-en commerci
believ strateg benefit combin
two busi expect financi benefit
realiz time although like limit
increment benefit manag target
estim increment annual revenu growth
three year follow octob close
merger manag also expect achiev million
outperform rate believ
opportun deliv faster revenu growth cost
synergi fulli reflect share current
valuat believ share move higher compani
abl deliv better-than-expect cross-sal
valuat move higher reflect earn growth
sale cost-synergi project
bloomberg capit market estim upside/downside/target
price target share base price-to-earnings multipl
appli ep estim
modest premium share trade sinc ipo
slightli histor premium
multipl believ premium histor multipl
justifi given synergi im merger compani
uniqu posit posit view biopharma
upsid scenario price share reflect
ep ahead current estim p/
 multipl believ upsid could driven
stronger-than-expect cro revenu growth greater
cross-sal client well increas merger synergi
downsid scenario price share reflect
ep growth current forecast
ep growth price-to-earnings ratio line
histor price-to-earnings ratio share
price target share base price-to-earnings multipl appli ep
estim modest premium share trade sinc ipo
slightli histor premium multipl believ premium
histor multipl justifi given synergi im merger compani uniqu
posit posit view biopharma spend price target support
risk rate price target
key risk biopharma spend trend execut merger integr project
sale cost synergi trend spend compani commerci solut
quintilesim creat octob merger quintil im health
busi oper three segment research develop commerci solut
integr engag servic compani provid outsourc real-world
evid solut biopharmaceut compani compani also provid solut
connect healthcar technology-en commerci oper
revenu
revenu
sell gener administr
revenu
adjust estim conting consider
revenu
loss extinguish debt
incom incom tax equiti earn unconsolid affili
incom equiti earn unconsolid affili
equiti earn unconsolid affili
net incom attribut non-controlling interest
net incom attribut quintil transnat hold
sale busi
